Abstract: Alisertib (MLN8237) is an investigational, highly selective small-molecule inhibitor of Aurora A kinase that has shown significant potential in the treatment of various malignancies, including Small Cell Lung Cancer (SCLC). SCLC is frequently driven by the amplification and overexpression of Myc-family oncogenes, which rely on Aurora A for protein stabilization. By acting as an ATP-competitive inhibitor, alisertib not only halts kinase activity but also induces an allosteric shift that disrupts the Aurora A/N-Myc complex, leading to the proteasomal degradation of N-Myc. In clinical settings, alisertib has demonstrated encouraging single-agent efficacy in both chemo-sensitive and chemo-resistant SCLC patients, prompting further investigation into combination therapies with agents such as paclitaxel and cisplatin. Despite its promise, the clinical utility of alisertib is currently limited by dose-limiting hematological toxicities, most notably neutropenia. Future perspectives focus on optimizing combination regimens, identifying predictive biomarkers for precision medicine, and utilizing alisertib-based PROTACs to fully degrade Aurora A and overcome resistance mechanisms.
1. Introduction
Small Cell Lung Cancer (SCLC) is a highly aggressive malignancy with a strong etiological link to the Myc-family of oncogenes, including MYC (c-Myc), MYCN (N-Myc), and MYCL1 (L-Myc). The amplification and overexpression of these genes are estimated to occur in 18 to 31% of SCLCs, driving tumor progression and poor prognosis [1]. Preclinical studies have established that SCLCs harboring Myc activation or amplification are notably sensitive to Aurora kinase inhibitors [1]. Aurora A kinase is a serine/threonine kinase essential for cell cycle regulation, mitotic entry, centrosome maturation, and spindle formation [2]. Its overexpression is frequently correlated with genomic instability, oncogenesis, and worsened patient survival outcomes [1]. Alisertib (MLN8237) is a highly selective, orally bioavailable small-molecule inhibitor of Aurora A kinase developed to target these vulnerabilities. It is currently being extensively evaluated in multiple cancer indications, with a strong scientific rationale supporting its clinical development strategy for SCLC as both a single agent and in combination with other therapies [1].
2. Pharmacological Activity
Alisertib has demonstrated potent pharmacological activity across a broad array of experimental tumor models in vitro and in vivo [1]. In viability screens of SCLC cell lines, alisertib was highly effective against MYC-amplified models [1]. This preclinical promise translated into clinical efficacy during a Phase 2 study of single-agent alisertib in advanced refractory or relapsed solid cancers. In this trial, objective partial responses were observed in 21% (10 out of 48) of enrolled SCLC patients [1]. Notably, these responses occurred in patients with both chemotherapy-sensitive and chemotherapy-resistant disease, highlighting its potential in relapsed settings [1].
Beyond monotherapy, alisertib exhibits synergistic pharmacological activity when combined with other agents. Preclinical models demonstrated that combining alisertib with cisplatin resulted in enhanced in vivo antitumor activity [1]. Furthermore, alisertib is being actively investigated in combination with microtubule-perturbing agents. A Phase 2 clinical trial (NCT02038647) is currently ongoing to evaluate the efficacy of alisertib in combination with paclitaxel compared to placebo plus paclitaxel in patients with second-line relapsed or refractory SCLC [1][2].
3. Molecular Mechanism of Action
Alisertib functions primarily as an ATP-competitive inhibitor that selectively binds to and inhibits Aurora A kinase [1][2]. The inhibition of Aurora A by alisertib leads to delayed mitotic entry and progression, resulting in an accumulation of cells with a tetraploid (4N) DNA content [1]. Treated cells exhibit severe mitotic defects, including monopolar, bipolar, and multipolar spindles with misaligned chromosomes. These cells subsequently undergo apoptosis, aneuploid cytokinesis, or mitotic slippage, ultimately leading to cell death or senescence [1]. In ovarian cancer models, alisertib has been shown to cause G2/M phase arrest followed by mitochondrial-mediated apoptosis through the inhibition of the PI3K/AKT/mTOR and p38 MAPK signaling pathways [4].
A critical secondary mechanism of action relevant to SCLC involves the destabilization of Myc proteins. Aurora A normally binds to and stabilizes N-Myc, protecting it from proteasomal degradation mediated by the FBXW7 E3 ubiquitin ligase [1]. When alisertib binds to the catalytic domain of Aurora A, it induces an allosteric conformational shift that disrupts the Aurora A/N-Myc interaction. Consequently, N-Myc is ubiquitinated by FBXW7 and degraded by the proteasome, effectively abrogating oncogenic N-Myc signaling [1][3].
4. Structure-Activity Relationship (SAR)
Alisertib is structurally characterized as a benzazepine-containing small molecule [1]. It was developed based on its predecessor, MLN8054, and exhibits greater than 200-fold selectivity for Aurora A over the structurally related Aurora B kinase in cellular assays [1][2]. As an ATP-competitive inhibitor, it targets the ATP-binding pocket at the active site of the kinase [2]. A unique structural feature of alisertib's binding is its ability to cause an allosteric shift at the Aurora A/N-Myc interaction site, a property that does not occur with all catalytic inhibitors of Aurora A [1].
Recent advancements in SAR have utilized the alisertib scaffold to design Proteolysis Targeting Chimeras (PROTACs). By linking alisertib via two or three ethylene glycol molecules to an E3-ubiquitin CEREBLON-binding ligand (such as thalidomide or pomalidomide), researchers have created bifunctional degraders [2]. These PROTACs induce rapid intracellular ubiquitination and proteasomal degradation of Aurora A. Importantly, this PROTAC-mediated depletion relies on the structural binding of the alisertib moiety rather than its catalytic inhibition, successfully degrading even enzymatically inactive mutated versions of Aurora A [2].
5. Current Limitations
The clinical application of alisertib is primarily limited by its toxicity profile. Because it acts as a cell cycle inhibitor in highly proliferative tissues, it induces significant myelosuppression. In clinical trials, the most common dose-limiting toxicities (DLTs) and Grade 3-4 adverse events include neutropenia, anemia, leukopenia, and thrombocytopenia [1]. Neutropenia is consistently reported as the most frequent dose-limiting toxicity requiring dose reduction [1]. Other common adverse effects include fatigue, stomatitis, alopecia, and gastrointestinal disorders (nausea, diarrhea) [1]. Additionally, patients have experienced somnolence and mood alterations, which are likely attributable to the benzodiazepine-like chemical structure of alisertib [1].
Another limitation is the complexity of determining optimal dosing regimens across various tumor types to maintain an acceptable risk/benefit profile, especially when combining alisertib with other chemotherapeutic agents that possess overlapping toxicities [1]. Furthermore, while alisertib shows single-agent activity, some Phase 3 trials in other indications (such as peripheral T-cell lymphoma) were discontinued because they did not meet primary endpoints for superior progression-free survival compared to standard care [1][2].
6. Future Perspectives
The future development of alisertib in SCLC and other cancers relies heavily on rational combination strategies and biomarker-driven patient selection. Preclinical data strongly support combining alisertib with targeted therapies—such as EGFR inhibitors, HDAC inhibitors, or immune checkpoint inhibitors (e.g., PD-L1 antibodies)—which may yield synergistic antitumor activity with a more favorable toxicity profile than traditional chemotherapy combinations [1][2]. Ongoing trials, such as the combination of alisertib with paclitaxel for SCLC, will be critical in defining its role in refractory settings [1].
Additionally, the identification of predictive biomarkers is essential for a precision medicine approach. Tumors with MYC or MYCN amplifications, or specific genetic mutations (such as RB1 loss, which is ubiquitous in SCLC), represent highly sensitive populations where alisertib could exploit synthetic lethality [1][2]. Finally, the development of alisertib-based PROTACs offers a novel therapeutic avenue. By degrading the Aurora A protein entirely, these molecules can eliminate both the catalytic and non-catalytic (scaffold) functions of the kinase, potentially overcoming resistance mechanisms that limit the efficacy of standard ATP-competitive inhibitors [2].
